CanSense
CanSense is a diagnostic company focused on early detection of bowel (colorectal) cancer through a non-invasive, cost-effective, and scalable blood test. Their technology combines laser spectroscopy with AI-driven data analytics to deliver a single streamlined liquid biopsy that detects cancer and pre-cancerous polyps early, reducing the need for invasive colonoscopies. The test aims to improve patient outcomes, reduce healthcare costs, and support pharmaceutical clinical trials. CanSense operates with a team of scientists, clinicians, and business experts, leveraging cutting-edge innovation to address a global health challenge with significant market potential in colorectal cancer diagnostics.
CanSense
CanSense is a diagnostic company focused on early detection of bowel (colorectal) cancer through a non-invasive, cost-effective, and scalable blood test. Their technology combines laser spectroscopy with AI-driven data analytics to deliver a single streamlined liquid biopsy that detects cancer and pre-cancerous polyps early, reducing the need for invasive colonoscopies. The test aims to improve patient outcomes, reduce healthcare costs, and support pharmaceutical clinical trials. CanSense operates with a team of scientists, clinicians, and business experts, leveraging cutting-edge innovation to address a global health challenge with significant market potential in colorectal cancer diagnostics.